MK-8776

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Hodgkin DiseaseLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveLeukemia, Lymphocytic, AcuteLymphoma, Non-HodgkinMyelogenous Leukemia, AcuteMyelogenous Leukemia, Chronic, Aggressive PhaseNeoplasms

Phase 1

A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)

CompletedNCT00779584

Merck Sharp & Dohme LLCHodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms

Start: 2008-10-17End: 2011-05-28Updated: 2018-08-27

Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)

TerminatedNCT00907517

Merck Sharp & Dohme LLCLeukemia, Lymphoblastic, Acute, Philadelphia-Positive, Leukemia, Lymphocytic, Acute, Myelogenous Leukemia, Acute +1

Start: 2009-07-29End: 2011-06-13Updated: 2018-08-27

Related Papers

Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

2012-10-2394 citations